Milligan Michael Lee
Insider CIK 1993953 · NMRA See Remarks
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| NMRA Neumora Therapeutics, Inc. | A Award deriv | 2026-08-20 | 2026-08-21 | 175,000 | — | $0 | 175,000 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award deriv | 2026-08-20 | 2026-08-21 | 175,000 | — | $0 | 175,000 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | S Sale | 2026-02-17 | 2026-02-19 | 1,436 | $3.57 | $5.1K | 21,034 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award deriv | 2026-01-08 | 2026-01-09 | 350,000 | — | $0 | 350,000 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | D To issuer deriv | 2025-05-28 | 2025-05-30 | 400,000 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award deriv | 2025-05-28 | 2025-05-30 | 41,250 | — | $0 | 41,250 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award deriv | 2025-05-28 | 2025-05-30 | 28,675 | — | $0 | 28,675 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award deriv | 2025-05-28 | 2025-05-30 | 38,234 | — | $0 | 38,234 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award deriv | 2025-05-28 | 2025-05-30 | 85,391 | — | $0 | 85,391 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award deriv | 2025-05-28 | 2025-05-30 | 400,000 | — | $0 | 400,000 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | D To issuer deriv | 2025-05-28 | 2025-05-30 | 41,250 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | D To issuer deriv | 2025-05-28 | 2025-05-30 | 28,675 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | D To issuer deriv | 2025-05-28 | 2025-05-30 | 38,234 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | D To issuer deriv | 2025-05-28 | 2025-05-30 | 85,391 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | S Sale | 2025-02-18 | 2025-02-20 | 1,978 | $1.69 | $3.3K | 22,470 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | D To issuer deriv | 2025-02-13 | 2025-02-18 | 41,250 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award deriv | 2025-02-13 | 2025-02-18 | 85,391 | — | $0 | 85,391 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award deriv | 2025-02-13 | 2025-02-18 | 38,234 | — | $0 | 38,234 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award deriv | 2025-02-13 | 2025-02-18 | 28,675 | — | $0 | 28,675 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award deriv | 2025-02-13 | 2025-02-18 | 41,250 | — | $0 | 41,250 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award deriv | 2025-02-13 | 2025-02-18 | 400,000 | — | $0 | 400,000 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | D To issuer deriv | 2025-02-13 | 2025-02-18 | 85,391 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | D To issuer deriv | 2025-02-13 | 2025-02-18 | 38,234 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | D To issuer deriv | 2025-02-13 | 2025-02-18 | 28,675 | — | $0 | 0 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award deriv | 2024-02-14 | 2024-02-16 | 41,250 | — | $0 | 41,250 | SEC↗ |
| NMRA Neumora Therapeutics, Inc. | A Award | 2024-02-14 | 2024-02-16 | 20,625 | — | $0 | 24,448 | SEC↗ |